Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2005 1
2008 2
2020 0
Text availability
Article attribute
Article type
Publication date

Search Results

3 results
Results by year
Filters applied: . Clear all
Page 1
Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial (ASSERT).
van der Heijde D, Dijkmans B, Geusens P, Sieper J, DeWoody K, Williamson P, Braun J; Ankylosing Spondylitis Study for the Evaluation of Recombinant Infliximab Therapy Study Group. van der Heijde D, et al. Arthritis Rheum. 2005 Feb;52(2):582-91. doi: 10.1002/art.20852. Arthritis Rheum. 2005. PMID: 15692973 Free article. Clinical Trial.
OBJECTIVE: The signs and symptoms of ankylosing spondylitis (AS) respond inadequately to nonsteroidal antiinflammatory drugs, corticosteroids, and disease-modifying antirheumatic drugs in quite a number of patients. ...Efficacy was assessed using the ASsessment in …
OBJECTIVE: The signs and symptoms of ankylosing spondylitis (AS) respond inadequately to nonsteroidal antiinflammatory drugs, …
Radiographic findings following two years of infliximab therapy in patients with ankylosing spondylitis.
van der Heijde D, Landewé R, Baraliakos X, Houben H, van Tubergen A, Williamson P, Xu W, Baker D, Goldstein N, Braun J; Ankylosing Spondylitis Study for the Evaluation of Recombinant Infliximab Therapy Study Group. van der Heijde D, et al. Arthritis Rheum. 2008 Oct;58(10):3063-70. doi: 10.1002/art.23901. Arthritis Rheum. 2008. PMID: 18821688 Free article. Clinical Trial.
OBJECTIVE: To evaluate the effect of infliximab on progression of structural damage over 2 years in patients with ankylosing spondylitis (AS). ...Radiographic progression of structural damage from baseline to the 2-year followup was scored using the modified Stoke …
OBJECTIVE: To evaluate the effect of infliximab on progression of structural damage over 2 years in patients with ankylosing spond
Efficacy and safety of infliximab in patients with ankylosing spondylitis over a two-year period.
Braun J, Deodhar A, Dijkmans B, Geusens P, Sieper J, Williamson P, Xu W, Visvanathan S, Baker D, Goldstein N, van der Heijde D; Ankylosing Spondylitis Study for the Evaluation of Recombinant Infliximab Therapy Study Group. Braun J, et al. Arthritis Rheum. 2008 Sep 15;59(9):1270-8. doi: 10.1002/art.24001. Arthritis Rheum. 2008. PMID: 18759257 Free article. Clinical Trial.
OBJECTIVE: To assess safety and efficacy of infliximab in patients with ankylosing spondylitis (AS) through 102 weeks. METHODS: Patients (n = 279) with active AS were randomized to either group 1 (n = 78; placebo through week 24 and then infliximab 5 mg/kg from week …
OBJECTIVE: To assess safety and efficacy of infliximab in patients with ankylosing spondylitis (AS) through 102 weeks. METHODS …
Feedback